List view / Grid view
After receiving an approval from France's National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announced the enrolment of the first patient in its first-in-human clinical trial in acute myeloid leukaemia.
Minoryx Therapeutics and the Neuraxpharm Group enter into a license agreement for the European rights to leriglitazone, which is currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).
GBF announces the manufacturing of the recombinant protein - Alzheimer’s disease vaccine, AV-1980R, for use in clinical trials.
Using AI, researchers have produced a nanozyme treatment for regenerating hair in mice, delivered via a microneedle.
COVID-19 has accelerated the decline in late-stage industry clinical research in the UK, compared to its global peers.
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
Apogenix’s asunercept demonstrates efficacy in Phase II trial for the treatment of hospitalised COVID-19 patients.
Yescarta approved by EC for the treatment of large B-Cell lypmphoma and high grade B-cell lymphoma.
CHMP issues positive opinion on Pluvicto®, paving the way for it to become the first European-approved radioligand therapy for metastatic prostate cancer patients.
The FDA has granted ODD to Telitacicept, produced by RemeGen, for the treatment of myasthenia gravis.
Results from a clinical study by Astellas have demonstrated the effectiveness of fezolinetant as a treatment for menopause-associated VMS.
